Aurora Cannabis: A Pivot to Global Medical Grows Patient by Patient
Despite Canadian reimbursement cuts, international medical expansion and EU GMP capacity drive Aurora's strategy.
ACB · Earnings Call · 2026-08-05
Aurora Cannabis reported its fiscal Q1 2027 results today, revealing a company firmly committed to its international medical cannabis strategy even as domestic headwinds bite. The international medical cannabis business grew 17% to $43 million, and for the first time, 64% of total net revenue came from outside Canada. CEO Miguel Martin opened the call by framing Aurora as a medical-first operator: “Aurora has become synonymous with medical cannabis in nationally legal markets because we spent years building the infrastructure, scientific capability, and regulatory expertise required to deliver reliable, scalable, and consistently high-quality products to patients.” — Miguel Martin, Executive Chairman and CEO · 2026-08-05
Navigating Regulatory Headwinds
The most pressing issue is the Canadian market, where a 30% reduction in the federal reimbursement rate for medical cannabis—the VAC program—took effect on April 1. CFO Simona King noted the impact: “we have seen an impact in Canadian medical on our revenues versus the prior quarters. That's a result of the reimbursement impact coming into effect on April 1, a 30% reduction in reimbursement rates.” — Simona King, Chief Financial Officer · 2026-08-05 Management is confident this is a temporary reset. Miguel Martin added, “there's a bit of a reset as it pertains to VAC, but we expect to grow share off of that.” — Miguel Martin, Executive Chairman and CEO · 2026-08-05 This Canadian medical headwind has been a recurring theme; on the June 2026 call, Miguel had already described the same impact: “Specifically, the VAC change, which was effective April one, is about a 30% reduction in the reimbursed rate for those products.” — Miguel Martin · 2026-06-11EU GMP and Safari: The Capacity Engine
Aurora's growth engine is its international capacity. The recent acquisition of Safari Flower Company—an EU GMP-certified cultivator—adds a 59,000-square-foot facility in Ontario. Miguel highlighted the certification milestone: “the fact they just received their GMP certification, which is valid for 3 years was very exciting for us, and we're thrilled.” — Miguel Martin, Executive Chairman and CEO · 2026-08-05 This aligns with the company's EU GMP strategy and its investment in plant science, which the company says can drive up to a 40% yield improvement on the same cost base. In the prior quarter, Simona reinforced this commitment, stating, “We're purposely investing in our international business to drive that growth in what we see in Europe and the other regions outside of Canadian medical.” — Simona King · 2026-06-11Looking to the U.S. and Beyond
The U.S. regulatory landscape is a fresh opportunity. Miguel outlined three areas—research collaborations, partnerships leveraging GMP standards, and potential import/export. He said, “we absolutely believe that there will be opportunities to partner.” — Miguel Martin, Executive Chairman and CEO · 2026-08-05 This is a longer-term option, but the near-term outlook remains bullish, as Simona noted in her prepared remarks:The company's confidence is anchored in its unique position, as Miguel summed up:For the fiscal second quarter, we expect revenue and adjusted EBITDA to be substantially higher than in the fiscal first quarter.
With a strong balance sheet, no debt, and nearly $150 million in cash, Aurora is positioned to weather the Canadian reset while investing in the international opportunities that define its future.We've established one of the most attractive medical cannabis growth businesses in the world.